Net Cash Provided by (Used in) Financing Activities of Protagenic Therapeutics, Inc.\new from 31 Mar 2016 to 30 Jun 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Protagenic Therapeutics, Inc.\new quarterly and annual Net Cash Provided by (Used in) Financing Activities in USD history and change rate from 31 Mar 2016 to 30 Jun 2025.
  • Protagenic Therapeutics, Inc.\new Net Cash Provided by (Used in) Financing Activities for the quarter ending 30 Jun 2025 was $4,422,960, a 359% increase year-over-year.
  • Protagenic Therapeutics, Inc.\new annual Net Cash Provided by (Used in) Financing Activities for 2024 was $1,963,546.
  • Protagenic Therapeutics, Inc.\new annual Net Cash Provided by (Used in) Financing Activities for 2021 was $12,577,664, a 928% increase from 2020.
  • Protagenic Therapeutics, Inc.\new annual Net Cash Provided by (Used in) Financing Activities for 2020 was $1,223,410, a 83% increase from 2019.
Source SEC data
View on sec.gov
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Change (%)
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Change (%)

Protagenic Therapeutics, Inc.\new Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q2 2025 $4,422,960 +$3,460,335 +359% 01 Apr 2025 30 Jun 2025 10-QT 10 Sep 2025 2026 Q1
Q1 2025 $102,519 01 Jan 2025 31 Mar 2025 10-Q 13 May 2025 2025 Q1
Q2 2024 $962,625 01 Apr 2024 30 Jun 2024 10-QT 10 Sep 2025 2026 Q1
Q1 2021 $127,125 -$202,875 -61% 01 Jan 2021 31 Mar 2021 10-Q 13 May 2022 2022 Q1
Q1 2020 $330,000 01 Jan 2020 31 Mar 2020 10-Q 17 May 2021 2021 Q1
Q1 2016 $3,797,250 01 Jan 2016 31 Mar 2016 10-Q 25 Jul 2016 2016 Q1

Protagenic Therapeutics, Inc.\new Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $1,963,546 01 Jan 2024 31 Dec 2024 10-K 31 Mar 2025 2024 FY
2021 $12,577,664 +$11,354,254 +928% 01 Jan 2021 31 Dec 2021 10-K 31 Mar 2023 2022 FY
2020 $1,223,410 +$553,410 +83% 01 Jan 2020 31 Dec 2020 10-K 07 Apr 2022 2021 FY
2019 $670,000 01 Jan 2019 31 Dec 2019 10-K 25 Mar 2021 2020 FY
2016 $4,283,938 01 Jan 2016 31 Dec 2016 10-K 02 Apr 2018 2017 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.